CD4 and disease arising from reactivation of latent virus: Yoder et al. also reported that the actin inhibitor jasplakinolide (Jas) effectively inhibited HIV latent infection of resting CD4 T cells at dosages around 120 nM when T cell activation was not inhibited by Jas [27].